Capricor Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update
Capricor Therapeutics (NASDAQ: CAPR) reported progress in the HOPE-3 Phase 3 clinical trial of CAP-1002 for Duchenne Muscular Dystrophy (DMD), alongside significant one-year results from the HOPE-2 study showing improved muscle function. The third-quarter financials reveal revenues of $1.6 million, driven by a $30 million payment from Nippon Shinyaku, while net loss increased to $6.4 million. With cash reserves of $46.6 million, Capricor anticipates funding through Q2 2024. The company is also advancing its StealthX™ platform for COVID-19 vaccines and exploring global partnerships.
- Enrollment in HOPE-3 trial is on track, advancing towards potential commercialization.
- Positive one-year results from HOPE-2 study showed significant muscle function improvement (p=0.02).
- Company reported $1.6 million in revenue, a notable increase from zero in Q3 2021.
- Cash and equivalents of $46.6 million expected to cover expenses into Q2 2024.
- Net loss increased to $6.4 million in Q3 2022 from $3.9 million in Q3 2021.
- Operating expenses rose significantly to $8.1 million in Q3 2022 compared to $4.3 million a year prior.
-Enrollment Continues to Progress in HOPE-3, the Pivotal Phase 3 Clinical Trial of CAP-1002 in Duchenne Muscular Dystrophy-
-Presented Positive One-Year Safety and Efficacy Results From HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy Patients at World Muscle Society 2022-
-Presented New Advances in Engineered Exosome Platform at Exosome-Based Therapeutic Development Summit-
-To Host Conference Call and Webcast Today at 4:30 p.m. ET-
SAN DIEGO, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, announced today its financial results for the third quarter ended September 30, 2022 and provided a corporate update.
“In the third quarter we continued to advance our late-stage clinical development program for CAP-1002 in patients with Duchenne Muscular Dystrophy (DMD), and took important steps toward potential commercialization,” said Linda Marbán, Ph.D., Capricor’s chief executive officer. “We are encouraged by the growing dataset including the statistically significant and clinically relevant data from the HOPE-2 open label extension trial which we recently presented at this year’s World Muscle Society Congress. These and prior results further support CAP-1002’s ability to improve both skeletal and cardiac muscle functions, which suggest potential disease modification, as well as the long-term safety profile of the therapy. Our main priority now is to continue to advance the ongoing HOPE-3 pivotal Phase 3 clinical trial. Patient dosing is underway and as enrollment progresses, we will continue to work closely with the FDA to define next steps in the regulatory pathway for CAP-1002 and at the request of the FDA, we have submitted the results from our HOPE-2 open label extension for their review. In parallel, we are exploring opportunities for additional strategic partnerships outside of the United States to allow for rapid therapy availability to the global patient community, if approved, and to maximize the value of this asset.”
Dr. Marbán continued, “Turning to our exosomes program, earlier this quarter, we presented results from our most advanced application of our proprietary StealthX™ platform for the production of a multivalent exosome-based vaccine or booster for COVID-19. Based on this unique platform, we were able to rapidly develop a protein-based vaccine that elicited a potent immune response without the need for an adjuvant or lipid nanoparticle carrier. We also continue to make progress with the second modality of this platform and are developing exosomes as precision delivery vehicles to more effectively bring a payload to targeted cells or tissues. In summary, we see our StealthX™ platform technology having the potential to support the next generation of vaccines and supporting the development of innovative therapeutics. We look forward to sharing further updates, including a planned publication of this preclinical work in the coming months.”
Third Quarter and Recent Operational Highlights
- HOPE-3, our pivotal, randomized, double-blind, placebo-controlled, Phase 3 clinical trial of CAP-1002 in DMD continues to progress well and enrollment remains on track (NCT05126758).
- Capricor continues its efforts toward potential commercialization, including manufacturing scale-up.
- Presented previously announced positive one-year results from our HOPE-2 open label extension study in patients with later-stage DMD. Treatment with CAP-1002 resulted in statistically significant clinical benefits in skeletal muscle function, observed by improvements in the Performance of the Upper Limb (PUL version 2.0) scale (p=0.02). Additionally, the results support potential disease modifying outcomes and reinforce the long-term safety potential of CAP-1002 in patients with DMD.
- Results were presented at a poster session at the World Muscle Society Congress (WMS) in Halifax, Nova Scotia, Canada on October 14, 2022.
- Presented new preclinical data on Capricor’s StealthX™ platform showing the rapid development of a recombinant protein-based vaccine for immunization and prevention against SARS-CoV-2, the virus causing COVID-19.
- These data were featured in a presentation at the 4th Exosome Based Therapeutic Development Summit, held in Boston, MA from October 4-6, 2022.
Anticipated Milestones and Events
The Company has set forth the following guidance for pipeline progression:
- Continue discussions with FDA regarding pathway towards a Biologics License Application or BLA for CAP-1002 in DMD
- Planned publication of preclinical work related to our StealthX™ engineered exosomes platform
- Planned interim analysis of HOPE-3 expected by mid-2023
- Full enrollment of HOPE-3 expected by the third quarter of 2023
Financial Results for Third Quarter 2022
Revenues: Capricor’s primary source of revenue was from the ratable recognition of the
Operating expenses: Total operating expenses for the three months ended September 30, 2022, were approximately
The Company reported a net loss of approximately
As of September 30, 2022, the Company’s cash, cash equivalents and marketable securities totaled approximately
Financial Outlook
Capricor expects that based on the current operating plan and financial resources, its available cash, cash equivalents and marketable securities will be sufficient to cover anticipated expenses and capital requirements into the second quarter of 2024. This expectation excludes any potential milestone payments under its commercialization and distribution agreement with Nippon Shinyaku as well as any strategic use of capital not currently in the Company’s base-case planning assumptions.
Conference Call and Webcast
To participate in the conference call, please dial 888-204-4368 (Domestic/Toll-Free) or 929-477-0402 (International) and reference the conference ID: 5157311. To participate via a webcast, please click here. The webcast will be archived for approximately 30 days and will be available at http://capricor.com/news/events/.
About Capricor Therapeutics
Capricor Therapeutics, Inc. (NASDAQ: CAPR) biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases. Capricor’s lead candidate, CAP-1002, is an allogeneic cardiac-derived cell therapy that is currently in late-stage clinical development for treating Duchenne muscular dystrophy. Capricor is also developing its exosome technology as a next-generation therapeutic platform. The Company’s current focus is on developing exosomes capable of delivering nucleic acids, including mRNA, as well as proteins to treat or prevent a variety of diseases. For more information, visit capricor.com, and follow the Company on Facebook, Instagram and Twitter.
Cautionary Note Regarding Forward-Looking Statements
Statements in this press release regarding the efficacy, safety, and intended utilization of Capricor’s product candidates; the initiation, conduct, size, timing and results of discovery efforts and clinical trials; the pace of enrollment of clinical trials; plans regarding regulatory filings, future research and clinical trials; regulatory developments involving products, including the ability to obtain regulatory approvals or otherwise bring products to market; the ability to achieve product milestones and to receive milestone payments from commercial partners; plans regarding current and future collaborative activities and the ownership of commercial rights; scope, duration, validity and enforceability of intellectual property rights; future royalty streams and revenue projections; expectations with respect to the expected use of proceeds from the recently completed offerings and the anticipated effects of the offerings; and any other statements about Capricor’s management team’s future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words “believes,” “plans,” “could,” “anticipates,” “expects,” “estimates,” “should,” “target,” “will,” “would” and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements. More information about these and other risks that may impact Capricor’s business is set forth in Capricor’s Annual Report on Form 10-K for the year ended December 31, 2021, as filed with the Securities and Exchange Commission on March 11, 2022 and in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2022 as filed with the Securities and Exchange Commission on August 12, 2022. All forward-looking statements in this press release are based on information available to Capricor as of the date hereof, and Capricor assumes no obligation to update these forward-looking statements.
CAP-1002 is an Investigational New Drug and is not approved for any indications. None of Capricor’s exosome-based candidates have been approved for clinical investigation.
For more information, please contact:
Capricor Media Contact:
Raquel Cona / Shana Marino
KCSA Strategic Communications
rcona@kcsa.com / smarino@kcsa.com
212.896.1204 / 347.487.6189
Capricor Investor Contact:
Joyce Allaire
LifeSci Advisors, LLC
jallaire@lifesciadvisors.com
617.435.6602
Capricor Company Contact:
AJ Bergmann, Chief Financial Officer
abergmann@capricor.com
310.358.3200
CAPRICOR THERAPEUTICS, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(UNAUDITED)
| Three months ended September 30, | Nine months ended September 30, | ||||||||||||||
| 2022 | 2021 | 2022 | 2021 | ||||||||||||
| REVENUE | |||||||||||||||
| Revenue | $ | 1,591,566 | $ | - | $ | 1,591,566 | $ | 244,898 | |||||||
| TOTAL REVENUE | 1,591,566 | - | 1,591,566 | 244,898 | |||||||||||
| OPERATING EXPENSES | |||||||||||||||
| Research and development | 5,504,356 | 2,513,915 | 15,585,143 | 9,307,512 | |||||||||||
| General and administrative | 2,564,960 | 1,800,630 | 7,637,461 | 5,496,186 | |||||||||||
| TOTAL OPERATING EXPENSES | 8,069,316 | 4,314,545 | 23,222,604 | 14,803,698 | |||||||||||
| LOSS FROM OPERATIONS | (6,477,750 | ) | (4,314,545 | ) | (21,631,038 | ) | (14,558,800 | ) | |||||||
| OTHER INCOME (EXPENSE) | |||||||||||||||
| Other income | - | 367,168 | 190,582 | 367,168 | |||||||||||
| Investment income | 106,635 | 15,570 | 141,836 | 41,476 | |||||||||||
| Forgiveness of debt | - | - | - | 318,160 | |||||||||||
| TOTAL OTHER INCOME (EXPENSE) | 106,635 | 382,738 | 332,418 | 726,804 | |||||||||||
| NET LOSS | (6,371,115 | ) | (3,931,807 | ) | (21,298,620 | ) | (13,831,996 | ) | |||||||
| OTHER COMPREHENSIVE INCOME (LOSS) | |||||||||||||||
| Net unrealized gain on marketable securities | 99,637 | - | 122,467 | - | |||||||||||
| COMPREHENSIVE LOSS | $ | (6,271,478 | ) | $ | (3,931,807 | ) | $ | (21,176,153 | ) | $ | (13,831,996 | ) | |||
| Net loss per share, basic and diluted | $ | (0.26 | ) | $ | (0.17 | ) | $ | (0.87 | ) | $ | (0.61 | ) | |||
| Weighted average number of shares, basic and diluted | 24,431,787 | 23,095,375 | 24,346,775 | 22,731,638 | |||||||||||
| CAPRICOR THERAPEUTICS, INC. | ||||||
| SUMMARY BALANCE SHEETS | ||||||
| September 30, 2022 (unaudited) | December 31, 2021 | |||||
| Cash, cash equivalents and marketable securities | $ | 46,613,512 | $ | 34,885,274 | ||
| Total assets | $ | 53,928,107 | $ | 41,330,323 | ||
| Total liabilities | $ | 38,501,615 | $ | 9,962,357 | ||
| Total stockholders' equity - 24,702,684 and 24,185,001 common shares issued and | ||||||
| outstanding at September 30, 2022 and December 31, 2021, respectively | 15,426,492 | 31,367,966 | ||||
| Total liabilities and stockholders' equity | $ | 53,928,107 | $ | 41,330,323 | ||
FAQ
What were Capricor's financial results for Q3 2022?
What are the results from the HOPE-2 study for CAP-1002?
What is the status of the HOPE-3 clinical trial for CAP-1002?
What does Capricor expect for its financial outlook?
What advancements have been made in Capricor's exosome platform?
